CHARACTERISTICS OF XDR M. TUBERCULOSIS STRAINS WITH SENSITITRE MYCOTB TEST-SYSTEM (background to make corrections in antituberculosis therapy of XDR-TB patients)
Abstract
We investigated 99 M. tuberculosis clinical isolates obtained from TB patients. Bactec MGIT 960 (Bactec960) and Sensititre MycoTB testsystem performed DST for antituberculosis drugs. All the investigated M. tuberculosis clinical isolates were XDR in Bactec960. The DST results performed by Sensititre MycoTB and Bactec960 showed a high rate of coincidence. On the other hand, the great number of investigated MTB isolates were detected as intermediately susceptible by Sensititre MycoTB test-system. It concerned to such useful drugs for combined chemotherapy as etambutol, maxifloxacin, ethionamide, kanamycin, ofloxacin, paraaminosalicylic acid, amikacin.
Information about intermediate susceptibility had a great practice value and gave a certain reserve for chemotherapy of such challenging category as XDR-TB patiens.
About the Authors
M. V. Makarova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
L. Yu. Krilova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
E. Yu. Nosova
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
V. I. Litvinov
ГБУЗ «Московский городской научно-практический центр борьбы с туберкулезом Департамента здравоохранения города Москвы»
Russian Federation
Russian Federation
References
1. Лабораторная диагностика туберкулеза / под ред. В.И. Литвинова, А.М. Мороза. – М.: МНПЦБТ. – 2001. – 176 с.
2. Литвинов В.И., Макарова М.В., Краснова М.А. Нетуберкулезные микобактерии // М.: МНПЦБТ. – 2008. – 255 с.
3. Abuali М., Katariwala R., LaBombardi V. A comparison of the Sensitive® MycoTB panel and the agar proportion method for the susceptibility testing of Mycobacterium tuberculosis. // Eur. J. Clin. Microbiol. Infect. Dis. – 2011. – Vol. 31. – N. 5. – P. 835-839.
4. Banu S., Rahman S., Khan M. et аl. Discordance across several methods for drug susceptibility testing of drug-resistant Mycobacterium tuberculosis isolates in a single laboratory. // J. Clin. Microbiol. – 2014. – Vol. 52. – N. 1. – P. 156-163.
5. Chiang C., Centis R., Migliori G. Drug-resistant tuberculosis: past, present, future. // Respirology. – 2010. – Vol. 15. – N. 3. – P. 413-432.
6. Daley C., Caminero J. Management of multidrug resistant tuberculosis. // Semin. Respir. Crit. Care Med. – 2013. – Vol. 34. – N. 1. – P. 44-59.
7. Giinther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. // Clin. Med. – 2014. – Vol. 14. – N. 3. – P. 279-285.
8. Hall L., Jude K., Clark S. et al. Antimicrobial susceptibility testing of Mycobacterium tuberculosis complex for first and second line drugs by broth dilution in a microtitre plate format. // J. Vis. Exp. – 2011. – Vol. 24. – N. 52. – P. 3094.
9. Heifets L. Drug susceptibility in the chemotherapy of mycobacterial infections. – CRC press, 1991. – 212 p.
10. Kalokhe A., Shafiq M., Lee J. et al. Multidrug-resistant tuberculosis drug susceptibility and molecular diagnostic testing. // Am. J. Med. Sci. – 2013. – Vol. 345. – N. 2. – P. 143-148.
11. Lee J., Armstrong D., Ssengooba W. et al. Sensititre MycoTB MIC plate for testing Mycobacterium tuberculosis susceptibility to first- and second-line drugs. // Antimicrob. Agents Chemother. – 2014. – Vol. 58. – N. 1. – P. 11-18.
12. Lynch J. Multidrug-resistant Tuberculosis. // Med. Clin. North. Am. – 2013. – Vol. 97. – N. 4. – P. 553–579.
13. Matteelli A., Roggi A., Carvalho A. Extensively drug-resistant tubercu-losis: epidemiology and management. // Clin. Epidemiol. – 2014. – Vol. l. – N. 6. – P. 111-118.
14. Mpagama S., Houpt E., Stroup S. et al. Application of quantitative second-line drug susceptibility at a multidrug-resistant tuberculosis hospital in Tanzania. // BMC Infect. Dis. – 2013. – Vol. 13. – P. 432-441.
15. Smith Т., Wolff K., Nguyen L. Molecular biology of drug resistance in Mycobacterium tuberculosis. // Curr. Top. Microbiol. Immunol. – 2013. – Vol. 374. – P. 53-80.
16. Use of liquid ТВ culture and drug susceptibility testing (DST) in low and medium income settings. / Summary report of the Expert Group Meeting on the Use of Liquid Culture Media. – Geneva: WHO, 2007.
17. WHO Guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. – Geneva: WHO, 2011.
18. WHO Guidelines for the programmatic management of drug-resistant tuberculosis. / Companion Handbook. – Geneva: WHO, 2014.
19. Zignol M. Drug-resistant tuberculosis in the WHO European Region: an analysis of surveillance data. // Drug Resist. Updat. – 2013. – Vol. 16. – N. 6. – P. 108-15.
Review
For citations:
Makarova M.V., Krilova L.Yu., Nosova E.Yu., Litvinov V.I. CHARACTERISTICS OF XDR M. TUBERCULOSIS STRAINS WITH SENSITITRE MYCOTB TEST-SYSTEM (background to make corrections in antituberculosis therapy of XDR-TB patients). Tuberculosis and socially significant diseases. 2016;(2):38-43. (In Russ.)
Views:
19
Email this article 